Project Eleven | $20,000,000 | (Jan 16, 2026)
CYB3R OPERATIONS | $5,400,000 | (Jan 16, 2026)
Quadric | $30,000,000 | (Jan 16, 2026)
Vitarka Therapeutics
United Kingdom
- London
- 12/04/2023
- Unknown
- $1,580,000
Curing the untreated: Vitarka Therapeutics is a pre-clinical biotech company determined to combat late-stage cancers.
- Industry Biotechnology Research
- Website https://www.vitarka.co.uk/
- LinkedIn https://www.linkedin.com/company/vitarka-therapeutics/
Related People
Vineeta TripathiFounder
United Kingdom -
London, England
15+ years’ in Pharmaceutical drug development for biologics within Neuroscience, Immuno-Oncology and Ophthalmology, project management, target product profile, go-to market strategy. Co-founded Vitarka Therapeutics, currently fundraising Seed investment round. Academic expertise in discovery and validation of TDP-43 mutations causing Motor Neuron Disease. Proven track record of publications in journals such as Science and Nature; total citation score of >7000. Co-inventor on patents for chimeric neurotoxin NMEs and therapeutic antibodies. Delivered 2 candidates to clinic for wet AMD. Won 3rd place for the 1st Roche pRED Oncology Award for innovative scientific achievements in “Novel highly tumor-selective membrane targets for antibody-based cancer therapy”.
GovDash | $30,000,000 | (Jan 16, 2026)
RouteSense | $2,000,000 | (Jan 16, 2026)
Vista AI | $29,500,000 | (Jan 16, 2026)
depthfirst | $40,000,000 | (Jan 16, 2026)
Slips | $3,500,000 | (Jan 16, 2026)
FOVC | $2,000,000 | (Jan 16, 2026)
VoiceRun | $5,500,000 | (Jan 16, 2026)
Emversity | $30,000,000 | (Jan 16, 2026)
Ammobia | $7,500,000 | (Jan 16, 2026)
Pinch AI | $5,000,000 | (Jan 16, 2026)